As the global pharmaceutical landscape evolves at an unprecedented pace, the need for a collaborative, science-first forum has never been more critical. This October 25–28, the American Association of Pharmaceutical Scientists (AAPS) will host its flagship event, PharmSci 360, at the Ernest N. Morial Convention Center in New Orleans. The conference promises to serve as a pivotal nexus for researchers, industry titans, and regulatory experts, offering a comprehensive look at the entire pharmaceutical product lifecycle.
With thousands of attendees expected, ranging from early-stage researchers to C-suite executives from industry giants like AstraZeneca, Merck, and the Mayo Clinic, the event is designed to tackle the most pressing challenges in drug development, from the initial bench-top discovery to the final regulatory submission.
The Core Mandate: Driving Science Forward
At its heart, AAPS PharmSci 360 is dedicated to the dissemination of actionable intelligence. The 2026 program is curated to address the "science-first" nature of the industry, ensuring that attendees walk away with concrete methodologies to accelerate drug development. The event focuses on the intersection of technological advancement and regulatory compliance, providing a platform where theoretical breakthroughs meet practical, large-scale manufacturing and clinical application.
The organizers have emphasized that this year’s iteration is particularly focused on "efficiency through innovation." By dissecting the roadblocks that cause development delays, the conference aims to provide a blueprint for faster, more sustainable drug delivery systems.
Chronology of Innovation: A Three-Day Deep Dive
The technical program for PharmSci 360 is structured to provide a logical flow of knowledge, starting with foundational development strategies and moving toward emerging clinical and regulatory paradigms.
Monday, October 26: The Architecture of Development
The opening day focuses on the operational and physiological mechanics of drug discovery. An executive-level track, "What Actually Drives Development Speed?", will feature an "autopsy" of industry delays, with insights from industry leaders like Dr. Leigh Verbois of Rx-360 and Teresa R. Henry of Blue Oaks Biotech.
Simultaneously, the technical sessions will dive into the complex world of predictive modeling. Key presentations include:
- Regulatory Readiness: Dr. Nagendra Chemuturi (Eli Lilly) will discuss the implementation of ICH S12 guidelines for biodistribution.
- Advanced Cell Models: Dr. Kim L.R. Brouwer (UNC Eshelman School of Pharmacy) will present on the integration of liver-on-a-chip systems and multicellular spheroids.
- Oncology Breakthroughs: A critical look at PD-L1 exosomes and their role in cancer resistance, led by Dr. Mandip Singh Sachdeva (Florida A&M University).
Tuesday, October 27: From Nanomedicine to Clinical Consequences
The second day shifts toward the translation of research into human health outcomes. This day is marked by a heavy emphasis on "New Approach Methodologies" (NAMs) and advanced human-mimetic systems.
- Quantitative Systems Toxicology: Dr. Jeffrey Woodhead (Simulations Plus) will explore how microphysiological systems are redefining toxicological safety.
- Clinical Realities: A highly anticipated session from Dr. Jessica Atieh (Mayo Clinic) will examine the clinical consequences of GLP-1-induced gastric emptying, a topic of intense interest given the current explosion in the obesity and diabetes drug market.
- Next-Gen Models: The afternoon will feature sessions on human lymphoid chip models for vaccine evaluation, presented by researchers from Merck, highlighting the push for more accurate human-based testing platforms.
Wednesday, October 28: Looking Toward the Future
The final day addresses the "Dose Code" and the regulatory landscape for pediatrics and sunlight-related health effects.
- Biologics: Dr. Ran Li (Genentech) will lead a session on modeling strategies for multispecific biologics.
- Regulatory Harmonization: A "Hot Topic" session will bring together regulators from Health Canada and the U.S. FDA to address whether international bodies are aligned on pediatric drug data, a fundamental hurdle for global market access.
Supporting Data: Innovator-Curated Tracks and Research Integrity
A significant evolution for the 2026 conference is the introduction of two Innovator-Curated tracks. Recognizing that scientific progress is only as reliable as its foundation, the organizers have prioritized research integrity and the ethical implementation of new methodologies.
On October 26, Brian Nosek will inaugurate the track on Research Integrity, featuring experts from the NIH and Northwestern University. This session aims to establish best practices for reproducibility in an era where data-driven drug discovery is increasingly reliant on complex algorithms and AI.
On October 28, the focus shifts to NAMs, curated by Dr. Thomas Hartung of Johns Hopkins University. This track will spotlight emerging companies like 28Bio and VeriSim Life, providing a glimpse into the future of drug testing that reduces animal reliance while increasing predictive accuracy.
Official Perspectives: Shaping the Future of Public Health
The conference is anchored by two keynote plenaries that frame the pharmaceutical industry’s role in the broader societal context.
Dr. Julie Gerberding, President and CEO of the Foundation for the National Institutes of Health (FNIH), will open the conference on October 25. Her expertise in public health policy is expected to set the tone for how private-sector innovation must align with global health priorities.
Closing the event on October 28, Dr. David Berry of Averin Capital will provide a venture-capital perspective on the transformation of the pharmaceutical market, emphasizing how disruptive technologies—from AI to synthetic biology—are shifting the financial and operational incentives of drug discovery.
Implications for the Industry: The New Collaborative Paradigm
Perhaps the most significant takeaway from PharmSci 360 is the emergence of the "Exhibition Hall" as an active learning environment. The new partnership between AAPS and the United States Pharmacopeia (USP) is a game-changer. By hosting sessions directly on the exhibit floor, the USP will offer real-time insights into excipient quality and inhalation standards, democratizing access to high-level regulatory guidance.
This environment fosters a unique synergy between service providers—such as Thermo Fisher Scientific, Agilent Technologies, and IQVIA—and the scientists who utilize these tools. For the attendee, this means the conference is not merely a venue for listening, but a hands-on experience in the future of the pharmaceutical toolkit.
Careers 360: Cultivating the Next Generation
A major implication of the conference’s structure is its dedication to workforce development. The Careers 360 initiative provides a comprehensive support system for researchers at all levels. By offering interactive sessions on AI skill-building, intellectual property management, and startup funding, AAPS is acknowledging that the modern pharmaceutical scientist must be a polymath—proficient in science, business, and digital literacy.
Conclusion: Why New Orleans Matters
The convergence of thousands of experts in New Orleans is more than just a networking opportunity; it is an essential calibration of the global drug development engine. As the industry faces increased scrutiny over development timelines, safety, and the efficacy of biologics, events like PharmSci 360 serve as the primary mechanism for correcting course and accelerating innovation.
For those looking to influence the next decade of pharmaceutical advancement, the program at the Ernest N. Morial Convention Center offers a roadmap through the complexities of modern medicine. Whether it is through the lens of regulatory alignment, the precision of organ-on-a-chip models, or the ethical imperative of research integrity, PharmSci 360 remains the definitive venue for the leaders who are shaping the future of health.
Interested professionals are encouraged to register and secure their place at the forefront of the industry by visiting the official AAPS PharmSci 360 portal.
About the Author
